Med Ad News held the 2016 Manny Awards in April, which featured a new category – Best POC (Point of Care) Campaign. Christine Franklin, executive director, The Point of Care Communication Council (PoC3), had the opportunity to talk with JUICE Pharma Marketing’s Justin Rubin, senior VP, group creative director, and Robert Palmer, executive VP, managing director, and understand more about the work they are doing.
Ogilvy CommonHealth Worldwide, the health behavior change specialists of Ogilvy & Mather and a WPP company, has launched the Ogilvy CommonHealth Marketing Cloud platform. The first of its kind, data-driven offering is anticipated to help marketers better understand, reach and engage with physicians on an individual level while sharing news of its newly formed partnership with Medikly, which is a leading provider of physician engagement solutions.
Amit D. Munshi became president, CEO and interim principal financial officer of Arena Pharmaceuticals Inc. effective May 11. Munshi joined Arena’s board of directors following the company’s June 2016 annual stockholders’ meeting.
After being abandoned as too ambitious in 1969, global plans to eliminate malaria are back on the agenda, with financial backing from the world’s richest couple, Bill and Melinda Gates, and U.S. President Barack Obama.
Kenneth S. Parks has become chief financial officer for Mylan N.V. According to executives, Parks joins Mylan with more than 30 years of corporate finance experience, including responsibilities across financial planning, accounting, investor relations, treasury, tax and information technology.
Astellas has made a series of new hires and appointments in its International Business, clinical, ethics and legal, and corporate departments. Rodrigo Fernandez has been made executive director, International Business, with responsibility for managing Astellas’ business in Latin America outside of Brazil.
Eisai has made three key appointments for its oncology and neurology business groups. Avinash Desai, M.D., has been made VP, Americas Oncology Medical Affairs for the Oncology Business Group (OBG) at Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co. Ltd. Beyhan Zaim was appointed VP Commercial Development & Alzheimer’s Disease Global Lead, Neurology Business Group. Paul Hawthorne is now senior VP, U.S. Commercial, Neurology Business Group.
Fredrik Wiklund has been made chief operating officer of Bioniz Therapeutics Inc.
More than two thirds of adults with uncontrolled asthma in the United States mistakenly believe that their condition is under control, according to the results of a survey released in May by GlaxoSmithKline. The survey results, researchers say, may suggest uncontrolled patients feel a false sense of confidence in managing their condition that may be driving recurring symptoms, and doctor, emergency room and urgent care visits.
The point of care health information services company ContextMedia:Health has announced the launch of its New Patient Start (NPS) Program, a new model that aims to change the way point-of-care programs are purchased and evaluated by pharmaceutical companies. ContextMedia:Health’s New Patient Start Program, company executives say, offers the ability for its brand partners to purchase marketing outcomes at no risk, and at a favorable ROI.
An experimental drug for RA from Johnson & Johnson and GlaxoSmithKline slowed joint damage and improved symptoms of the disease, meeting the main goals of a large, late-stage trial.
A U.S. advisory panel recommended approving Teva Pharmaceutical Industries’ long-acting opioid painkiller Vantrela ER, saying data showed it has some abuse-resistant properties.
Synthetic designer drugs, especially synthetic opioids like fentanyl implicated in the death of pop star Prince, pose an “unprecedented” threat for U.S. overdoses and deaths – especially among youth – the country’s top anti-drug official said.
An experimental wearable artificial kidney shows promise as a substitute for dialysis machines, researchers report.
Obesity rates for U.S. women and teens are on the rise, according to two new studies from the U.S. Centers for Disease Control and Prevention (CDC) published in JAMA.
A preliminary regulatory review of Merck & Co. Inc.’s experimental drug to treat the most common cause of infectious diarrhea often found in hospitals and nursing homes questioned whether the drug’s efficacy had been adequately demonstrated.
Biogen Inc.’s keenly watched experimental drug for treating multiple sclerosis failed to meet the main goal of improving some symptoms in a mid-stage study.
Climatic Change, actuality or total fantasy? Global warming has long been the very best press for this sort of a while, sure this issue is very sensitive as the ecologists encountered a great explanation to your weather conditions adjustments, the important unfavorable wolf in the modern environment would be the market place as well as […]
Genentech and OSI Pharmaceuticals have been ordered to pay $67 million to resolve allegations they made misleading statements about the effectiveness of the oral cancer drug Tarceva to treat non-small cell lung cancer, the U.S. Department of Justice announced.
A federal court judge reversed a $200 million award against Gilead over claims of patent violations for its hep C drugs due to patterns of misconduct by Merck & Co.